ALCIDION GROUP LIMITED (ALC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ALC

ALC - ALCIDION GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.35
Index:

Alcidion Group provides clinical information technology to support clinicians in decision making, ensuring quality of care for patients. The company operates in Australia and the UK. It listed on the ASX in 2011.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.102

30 Apr
2026

-0.006

OPEN

$0.11

-5.56%

HIGH

$0.11

132,426

LOW

$0.10

TARGET
$0.16 56.9% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . BMT . DOC . EBO . HLS . IDX . M7T . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
ALC: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 0.1 0.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A - 16.7% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 100.0 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx0.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx40.8 M
Book Value Per Share xxxxxxxxxxxxxxx6.5
Net Operating Cash Flow xxxxxxxxxxxxxxx5.8 M
Net Profit Margin xxxxxxxxxxxxxxx4.06 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx1.89 %
Return on Invested Capital xxxxxxxxxxxxxxx1.87 %
Return on Assets xxxxxxxxxxxxxxx1.44 %
Return on Equity xxxxxxxxxxxxxxx1.89 %
Return on Total Capital xxxxxxxxxxxxxxx-0.63 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx5.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx68 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx18 M
Price To Book Value xxxxxxxxxxxxxxx1.53

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx0.31 %
Cost of Goods Sold xxxxxxxxxxxxxxx36 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

30/04/2026

1

Buy

$0.16

56.86%

Alcidion Group's 3Q26 update is viewed as "solid" by Bell Potter with contracted revenue for FY26 at $43.8m a rise of $0.7m at the end of the prior quarter.

Contract value sales came in at $11.7m and year-to-date at $35.5m, which the analyst flags should lift to over $70m over 4Q26 assuming a contract with UHSussex is signed in May.

Management reiterated guidance of revenue over $50m and earnings (EBITDA) of over $5m which is considered as very achievable.

Buy rating and 16c target are retained.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.10 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Moelis

05/03/2026

1

Initiation of coverage with Buy

$0.15

47.06%

Alcidion Group has executed a decade of capability expansion, international growth and product investment supporting larger, longer deployments, earning a Buy rating upon first-time coverage by Moelis. A 15c target is set.

The broker considers healthcare digitisation, interoperability demand and NHS electronic patient record contracts key growth drivers for this health technology company. 

The analyst points to FY25 improvement with positive earnings (EBITDA) and cashflow, while FY26 guidance implies consolidation or improvement, signalling increasing financial sustainability as scale builds.

Alcidion competes with large US based EPR vendors such as EPIC, Cerner (Oracle Health), Altera, and Meditech, cautions Moelis.

Competition also derives from legacy vendors controlled by Private Equity (System C, Access Rio) alongside a growing cohort of modular, workflow-focused platforms similar to its own solution.

The analyst observes additional growth potential through upselling existing clients, expanding in A&NZ and the UK, plus planned entry into Canada and the Middle East.

FORECAST
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.10 cents.
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.10 cents.
Access Extra Coverage Research History >

ALC STOCK CHART

FNArena News on ALC

Latest Healthcare services News

1
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
2
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
3
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals
4
Funding Overhang Weighs On Ramsay’s Rebound

Jun 10 2021 - Australia
5
Treasure Chest: More Pfizer Growth For Ebos Group

May 24 2021 - Treasure Chest
6
Treasure Chest: Demand Pumps Ramsay Health

Mar 03 2021 - Treasure Chest
7
Healius Enjoying Testing Times

Dec 11 2020 - Australia
8
The First Connection

Dec 10 2020 - Weekly Reports
9
Subdued Recovery For Ramsay Health Care

Nov 16 2020 - Australia
10
Recovery Underway For Sonic Healthcare

Jun 25 2020 - Australia